1. Co-activation of NF-κB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability
- Author
-
Barbosa, RR, Xu, AQ, D’Andrea, D, Copley, F, Patel, H, Chakravarty, P, Clear, A, Calaminici, M, Janz, M, Zhang, B, Schmidt-Supprian, M, Wang, J, Gribben, JG, Tooze, R, Fitzgibbon, J, Franzoso, G, Rajewsky, K, Calado, DP, Medical Research Council (MRC), Cancer Research UK, Bloodwise, and Imperial College Healthcare NHS Trust- BRC Funding
- Abstract
NF-κB and MYC are found co-deregulated in human B and plasma-cell cancers. In physiology, NF-κB is necessary for terminal B-to-plasma cell differentiation, whereas MYC repression is required. It is thus unclear if NF-κB/MYC co-deregulation is developmentally compatible in carcinogenesis and/or impacts cancer cell differentiation state, possibly uncovering unique sensitivities. Using a mouse system to trace cell lineage and oncogene activation we found that NF-κB/MYC co-deregulation originated cancers with a plasmablast-like phenotype, alike human plasmablastic-lymphoma and was linked to t(8;14)[MYC-IGH] multiple myeloma. Notably, in contrast to NF-κB or MYC activation alone, co-deregulation rendered cells addicted to IL6 for survival and phenotypic stability. We propose that conflicting oncogene-driven differentiation pressures can be accommodated at a cost in poorly-differentiated cancers.
- Published
- 2020